Skip to content

Effect of in vitro focused ultrasound on conformal ablation and tumor-specific immunity in prostate cancer target area

Effect of in vitro focused ultrasound on conformal ablation and tumor-specific immunity in prostate cancer target area

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063842
Enrollment
Unknown
Registered
2022-09-19
Start date
2022-09-19
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

1:Focused ultrasound ablation

Sponsors

Zigong Fourth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients over 18 years of age; 2. Clinically confirmed prostate cancer patients with indications for radical prostatectomy; 3. Safe acoustic path and focus can reach the target area; 4. Monitoring ultrasound can show the lesions.

Exclusion criteria

Exclusion criteria: 1. History of prostate surgery; 2. History of prostate radiation therapy/local particle implantation; 3. History of other local prostate treatments (including radiofrequency ablation, cryotherapy, etc.); 4. Rectal lesions; 5. Urethral stenosis/deformity; 6. Bladder detrusor weakness; 7. There are calcifications in the prostate adjacent to the rectal wall; 8. Bladder or lower urinary tract stones; 9. Poor blood sugar control in diabetes; 10. Severe renal dysfunction; 11. The stone cutting position cannot be taken; 12. Those with strong sexual/reproductive requirements; 13. Contraindications to MRI; 14. Merge with other malignant tumors; 15. Concomitant severe heart, lung, and brain diseases.

Design outcomes

Primary

MeasureTime frame
Ablation rate;

Secondary

MeasureTime frame
Coagulative necrosis;Prostate specific antigen, PSA;Tumor-specific immune related indicators;

Countries

China

Contacts

Public ContactYong Liang

Zigong Fourth People's Hospital

urologyly@163.com+86 13909006619

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026